Skip to main content
SpringerLink
Log in
Book cover

Psoriasis and Psoriatic Arthritis pp 193–222Cite as

Psoriasis

  • Chapter

  • 1345 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   159.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyteassociated antigen 4-immunoglobin (CTLA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192: 681–694

    Article  PubMed  CAS  Google Scholar 

  2. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S (1999) CTLA41g-medicated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243–1252

    Article  PubMed  CAS  Google Scholar 

  3. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J (1998) Administration of DAB3891L-2 to patients with recalcitrant psoriasis: a double blind, phase II multicenter trial. J Am Acad Dermatol 38: 938–944

    Article  PubMed  CAS  Google Scholar 

  4. Biogen, Inc. Amevive (Alefacept) Briefing Document. Dermatologic and Ophthalmic Drugs Advisory Meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing.3865B1_Biogen.pdf

    Google Scholar 

  5. Biogen Inc. Amevive (Alefacept) US Product Monograph. Available at: http://www.Amevive.com/en_US/fragment/portlet/FINAL_Amevive_Label.pdf

    Google Scholar 

  6. Danielian S, Fagard R, Alcover A, Acuto O, Fischer S (1991) The Tyrosine kinase activity of p56lck is increased in human T-cells activated via CD2. Eur J Immunol 21: 1967–1970

    Article  PubMed  CAS  Google Scholar 

  7. Deckert F, Legay F (1999) Development and validation of an immunoreceptor assay for simulect based on surface plasmon resonance. Anal Biochem 274: 81–89

    Article  PubMed  CAS  Google Scholar 

  8. Dustin ML, Springer TA (1988) Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107: 321–331

    Article  PubMed  CAS  Google Scholar 

  9. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345: 248–255

    Article  PubMed  CAS  Google Scholar 

  10. Ellis CN, Mordin MM, Adler EY (2003) Effects of Alefacept on health-related quality of life in patients with psoriasis. Am J Clin Dermatol 4: 131–139

    Article  PubMed  Google Scholar 

  11. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM (2000) CD69, HLA-DR and the IL-2R identify persistency activated T cells in psoriasis vulgaris lesional skin: blood and skin comparison by flow cytometry. J Autoimmun 14: 63–78

    Article  PubMed  CAS  Google Scholar 

  12. Genentech Inc. Raptiva (Efalizumab) US Product Monograph Available at: http://www.gene.com/gene/products/information/immunological/raptiva/insert.jsp

    Google Scholar 

  13. Gniadecki R, Zachariae C, Calverley M (2002) Trends and developments in the pharmacological treatment of psoriasis. Acta Derm Venereol 82: 401–410

    Article  PubMed  CAS  Google Scholar 

  14. Gordon KB (2004) Efficacy of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  15. Gordon KB, Langley RG (2003) Remittive effects of intramuscular Alefacept in psoriasis. J Drugs Dermatol 2: 624–628

    PubMed  Google Scholar 

  16. Gordon KB, Papp KA, Hamilton RTC, Vilieke PA, Dunner W, Li N, Bresnahan BW, Merter A (2003) Efalizumb for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Jama 290: 3073–3080

    Article  PubMed  CAS  Google Scholar 

  17. Gordon KB, West DP (2001) Biologic therapy in dermatology. In: Wolverton SE (ed) Comprehensive dermatologic drug therapy. WB Saunders, Philadelphia, pp 928–942

    Google Scholar 

  18. Gottlieb A (2004) Alefacept in combination with tapering doses of cyclosporine in patients with psoriasis. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  19. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB (2003) CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 49: 816–825

    Article  PubMed  Google Scholar 

  20. Gottlieb AB, Gordon K, Caro I, Li N, Chastain RL, Leonardi CL (2004) Long-term Efalizumab therapy safely maintains psoriasis area and severity index improvement: preliminary results from an open-label trial. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  21. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garavoy M (2000) Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 42: 428–435

    Article  PubMed  CAS  Google Scholar 

  22. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M (2002) Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizaumab, an anti-CD11a antibody. Arch Dermatol 138: 591–600

    Article  PubMed  CAS  Google Scholar 

  23. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43: 595–604

    Article  PubMed  CAS  Google Scholar 

  24. Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, Ling M, Magee A, McCall CO, Rist T, Dummer W, Walicke P, Bauer RF, White M, Garovoy M (2003) Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 198–207

    Google Scholar 

  25. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1: 442–447

    Article  PubMed  CAS  Google Scholar 

  26. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141: 264–273

    Article  PubMed  CAS  Google Scholar 

  27. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M (2004) Safety and efficacy of an extended 16-week course of alefacept in the treatment of chronic plaque psoriasis: an interim analysis. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  28. Krueger GG, Callis KP (2003) Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 49: S87–97

    Article  PubMed  Google Scholar 

  29. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN (2002) A randomized, double blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47: 821–833

    Article  PubMed  Google Scholar 

  30. Krueger GG, Vaishnaw A, Gordon K (2002) Alefacept (LFA-3/IgG1), a fully human fusion protein, is non-immunogenic in patients with chronic psoriasis (poster #P583). Presented at the 60th Annual Meeting of the American Academy of Dermatology; February 22–27; New Orleans, LA

    Google Scholar 

  31. Krueger GG, Van de Kerkhof P (2004) Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  32. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1–23

    Article  PubMed  Google Scholar 

  33. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, Sherr A, Gottlieb AB (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448–458

    Article  PubMed  CAS  Google Scholar 

  34. Kuypers TW, Roos D (1989) Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 140: 461–486

    Article  PubMed  CAS  Google Scholar 

  35. Langley R, Baker D, Roberts J (2004) The safety of alefacept using a reduced schedule for monitoring T cells. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  36. Lebwohl M, Christophers E, Langley R, Ortonne JP, Griffiths CE (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139: 791–793

    Article  Google Scholar 

  37. Lebwohl M, Gordon K, Lowe N, et al. (2002) Safety profile of alefacept: pooled results of placebo-controlled trials (abstract no. P1993) Ann Dermatol Venereol 129(Suppl): 1S761

    Google Scholar 

  38. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy M, Pariser D (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004–2013

    Article  PubMed  CAS  Google Scholar 

  39. Leonardi C (2004) Efalizumab (Raptiva): A new therapeutic option for the long-term management of plaque psoriasis. Psoriasis Forum: Spring

    Google Scholar 

  40. Leonardi CL (2003) Efalizumab: an overview. J Am Acad Dermatol 49: S98–104

    Article  PubMed  Google Scholar 

  41. Leonardi CL, Goffe B, Sobell J, Caro I, Wang X, Papp KA (2004) The safety of Efalizumab in patients with moderate to severe plaque psoriasis: summary of clinical trial experience. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  42. Majeau GR, Meier B, Jimmo D, Kioussis PS (1994) Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 152: 2753

    PubMed  CAS  Google Scholar 

  43. Mehlis SL, Gordon KB (2003) The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 49: S44–50

    Article  PubMed  Google Scholar 

  44. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vitro pharmacology. Br J Dermatol 137: 568–576

    Article  PubMed  CAS  Google Scholar 

  45. Menter A, Abramovits W, Cather JC (2004) Alefacept in combination with tapering doses of methotrexate in patients with psoriasis. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  46. Menter A, Cather JC (2004) Long term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  47. Menter A, Cather JC, Abramovits W (2004) Tuberculosis testing and the use of biologic therapies for the treatment of psoriasis. Poster presented at: 62nd Annual American Academy of Dermatology Meeting; February 6–11; Washington, DC

    Google Scholar 

  48. Poole R (2002) Alefacept: An effective therapy for psoriasis. Inpharma 1328: 9–11

    Google Scholar 

  49. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa M D, Wallner BP (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178: 211

    Article  PubMed  CAS  Google Scholar 

  50. Owen CM, Harrison PV (2000) Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 25: 195–197

    Article  PubMed  CAS  Google Scholar 

  51. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45: 665–674

    Article  PubMed  CAS  Google Scholar 

  52. Papp K, Ellis C, Menter A, et al. (2002) Alefacept improves psoriasis and quality of life: results of a multiple-course trial (abstract no. P2012). Anal Dermatol Venereol 129(Suppl): S764

    Google Scholar 

  53. Poulin YP, Lynde C, Lauzon G, Gupta AK, Barber K, Hull PR, Gilliver WP, Toth D, Gratton D, Langley RGB, Yatscoff R (2004) A randomized, multicenter, double blind, placebo controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Cutan Med Surg (in press)

    Google Scholar 

  54. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberhauer R, Stuetz A, Wolff K (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876–887

    Article  PubMed  CAS  Google Scholar 

  55. Vaishnaw AK (2002) Pharmacokinetics, biologic activity, and tolerability of Alefacept by intravenous and intramuscular administration. J Pharmatokinet Pharmacodyn 29: 415–426

    Article  CAS  Google Scholar 

  56. Weinberg JM, Tutrone WD (2003) Biologic therapy for psoriasis: the T-cell targeted therapies — efalizumab and alefacept Cutis 71: 4

    Google Scholar 

References

  1. Adalimumab (2004) Package insert

    Google Scholar 

  2. Ameglio F, et al. (1994) Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 189: 359–363

    PubMed  CAS  Google Scholar 

  3. Amgen, Data on File

    Google Scholar 

  4. Anker S, Coats A (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86: 123–130

    Article  PubMed  Google Scholar 

  5. Anonymous (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53: 457–465

    Google Scholar 

  6. Bonifati C, et al. (1994) Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients — relationships with disease severity. Clin Exp Dermatol 19: 383–387

    Article  PubMed  CAS  Google Scholar 

  7. Chaudhari U. et al. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357: 1842–1847

    Article  PubMed  CAS  Google Scholar 

  8. Chung E, et al. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133–3140

    Article  PubMed  CAS  Google Scholar 

  9. Cohen R, Tsang J, Hanauer S (2000) Infliximab in Crohn’s disease: First anniversary clinical experience. Am J Gastroenterol 95: 3469–3477

    Article  PubMed  CAS  Google Scholar 

  10. Elewski B, et al. (2004) Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study. J Am Acad Dermatol 50: P159

    Article  Google Scholar 

  11. Etanercept (2004) Package insert

    Google Scholar 

  12. Ettehadi P, et al. (1994) Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146–151

    PubMed  CAS  Google Scholar 

  13. FDA (2003) Briefing document. Arthritis advisory meeting

    Google Scholar 

  14. Furst D, et al. (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30: 2563–2571

    PubMed  CAS  Google Scholar 

  15. Garcia-Planella E, et al. (2003) Development of antinuclear antibodies and its clinical impact in patients with Crohn’s disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 15: 351–354

    Article  PubMed  CAS  Google Scholar 

  16. Gelfand J, et al. (2003) Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 139: 1425–1429

    Article  PubMed  Google Scholar 

  17. Gottlieb A, et al. (2004) The efficacy of infliximab across a variety of subgroups with plaque psoriasis. J Am Acad Dermatol 50: P158

    Google Scholar 

  18. Gottlieb A, et al. (2004) Withdrawal from etanercept after successful clinical response in psoriasis patients: Disease characteristics and the durability of treatment response. J Am Acad Dermatol 50: P146

    Article  Google Scholar 

  19. Gottlieb AB, et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139: 1627–1632

    Article  PubMed  CAS  Google Scholar 

  20. Infliximab (2004) Package insert

    Google Scholar 

  21. Keystone E, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400–1411

    Article  PubMed  CAS  Google Scholar 

  22. Klapman J, et al. (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9: 176–178

    Article  PubMed  Google Scholar 

  23. Kwon H, et al. (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138: 807–811

    PubMed  Google Scholar 

  24. Leonardi C, et al. (2004) The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse. J Am Acad Dermatol 50: P146

    Article  Google Scholar 

  25. Leonardi CL, et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022

    Article  PubMed  CAS  Google Scholar 

  26. Lipsky P, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602

    Article  PubMed  CAS  Google Scholar 

  27. Maini R, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354: 1932–1939

    Article  PubMed  CAS  Google Scholar 

  28. Maini RN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563

    Article  PubMed  CAS  Google Scholar 

  29. Margolis D, et al. (2001) The risk of malignancy associated with psoriasis. Arch Dermatol 137: 778–783

    PubMed  CAS  Google Scholar 

  30. Mease PJ, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390

    Article  PubMed  CAS  Google Scholar 

  31. Mikuls T, Weaver A (2003) Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheum Rep 5: 270–277

    Article  Google Scholar 

  32. Mohan N, et al. (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862–2869

    Article  PubMed  CAS  Google Scholar 

  33. Moreland L, Cohen S, Klareskog L (2002) Global safety and efficacy of more than 5 years of etanercept (ENBREL) therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 46(Suppl): S532

    Google Scholar 

  34. Moreland LW, et al. (1996) Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23: 1849–1855

    PubMed  CAS  Google Scholar 

  35. Nickoloff B, et al. (1991) Cellular localization of interleukin-8 and its inducer, tumor necrosis factoralpha, in psoriasis. Am J Pathol 138: 129–140

    PubMed  CAS  Google Scholar 

  36. Ogilvie AL, et al. (2001) Treatment of psoriatic arthritis with antitumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144: 587–589

    Article  PubMed  CAS  Google Scholar 

  37. Oh CJ, Das KM, Gottlieb AB (2000) Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42: 829–830

    Article  PubMed  CAS  Google Scholar 

  38. O’Quinn RP, Miller JL (2002) The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis. Arch Dermatol 138: 644–648

    Article  PubMed  Google Scholar 

  39. Sagawa Y, et al. (1993) Is sustained production of tumor necrosis factor-a relevant to the development of pustular psoriasis? Dermatology 187: 81–83

    Article  PubMed  CAS  Google Scholar 

  40. Sarzi-Puttini P, et al. (2003) Infliximab-induced lupus in Crohn’s disease: a case report. Digest Liver Dis 35: 814–817

    Article  CAS  Google Scholar 

  41. Shakoor N, et al. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579–580

    Article  PubMed  CAS  Google Scholar 

  42. Stratigos A, et al. (2004) Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol 29: 150–153

    Article  PubMed  CAS  Google Scholar 

  43. Strober B (2003) Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 140: 366

    Article  Google Scholar 

  44. Swale V, et al. (2003) Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 28: 604–607

    Article  PubMed  CAS  Google Scholar 

  45. Symmons D, Silman A (2004) Anti-tumor necrosis alpha therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis Rheum 50: 1703–1706

    Article  PubMed  Google Scholar 

  46. Uyemura K, et al. (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101: 701–705

    Article  PubMed  CAS  Google Scholar 

  47. van de Putte L, et al. (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63: 508–516

    Article  PubMed  CAS  Google Scholar 

  48. Wallace K, et al. (2004) Results of the DLQI dermatology-specific quality of life measure in moderate to severe plaque psoriasis patients receiving 24 weeks of adalimumab therapy. American Academy of Dermatology Annual Summer Meeting, 2004, New York

    Google Scholar 

  49. Weinblatt M, Kremer J, Bankhurst A (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253–259

    Article  PubMed  CAS  Google Scholar 

  50. Weinblatt M, Keystone E, Furst D (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35–45

    Article  PubMed  CAS  Google Scholar 

  51. Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: The effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740–1751

    Article  PubMed  CAS  Google Scholar 

  52. Zeltser R, et al. (2001) Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor-α receptor: Fc fusion protein. Arch Dermatol 137: 893–899

    PubMed  CAS  Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. Division of Dermatology, Loyola University, Stritch School of Medicine, 2160 S. First Ave., Building 112, Room 342, Maywood, IL, 60153, USA

    Kenneth B. Gordon MD

  2. Division of Rheumatology, Northwestern University, Feinberg School of Medicine, 675 N. St. Clair St., Chicago, IL, 60611, USA

    Eric M. Ruderman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2005). Psoriasis. In: Gordon, K.B., Ruderman, E.M. (eds) Psoriasis and Psoriatic Arthritis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27190-2_18

Download citation

  • DOI: https://doi.org/10.1007/3-540-27190-2_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21280-5

  • Online ISBN: 978-3-540-27190-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation